Drugs / CAR-T/CAR-NK cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06596057 | Feb 2024 → Jun 2026 overdue | — | The Second Hospital of Shandong University | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-T/CAR-NK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06596057 ↗ |
| Modality | Cell therapy | “CAR-T/CAR-NK cells” NCT06596057 ↗ |
| Route | Intravenous | “Single intravenous infusion.” NCT06596057 ↗ |
| Target | CD19 | “Safety and Efficacy of CD19 CAR-T/CAR-NK Cells” NCT06596057 ↗ |